HPV vaccine

$16.5 Billion Cervical Cancer Screening Markets, 2026

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Infectious causes of cancer, Gynaecological cancer, Medicine, Clinical medicine, Cervical cancer, Cervical screening, Screening, Epidemiology of cancer, Preventive healthcare, HPV vaccine

Global Cervical Cancer Screening Market is expected to be USD 16.5 Billion by 2026.

Key Points: 
  • Global Cervical Cancer Screening Market is expected to be USD 16.5 Billion by 2026.
  • Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences.
  • As preventive measures should put in place during the efforts of providing cervical cancer screening as directed by the health authorities.
  • Read the complete analysis on how COVID-19 has affected the cervical cancer screening market and its future?

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Clinical medicine, Medical specialties, Gynaecological cancer, Vaccines, Cancer vaccines, HPV vaccine, Human papillomavirus infection, Cervical cancer, Vaccine

Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).

Key Points: 
  • Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.

Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Gynaecological cancer, HPV vaccine, Human papillomavirus infection, Vaccine, Papillomaviridae

The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.

Key Points: 
  • The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.
  • "North America (has recently) held the largest HPV vaccines market share with a revenue of USD 1.83 billion.
  • The rise in preference for vaccination and treatment at the nearest healthcare institution will also add impetus to the regional market growth."
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.

Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Gynaecological cancer, HPV vaccine, Human papillomavirus infection, Vaccine, Papillomaviridae

The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.

Key Points: 
  • The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.
  • "North America (has recently) held the largest HPV vaccines market share with a revenue of USD 1.83 billion.
  • The rise in preference for vaccination and treatment at the nearest healthcare institution will also add impetus to the regional market growth."
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Medical specialties, Clinical medicine, Papillomavirus, Infectious causes of cancer, Vaccination, Vaccines, Gynaecological cancer, HPV vaccine, Vaccine, Human papillomavirus infection, Cancer vaccine

BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."

Key Points: 
  • BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.Yann Gaslain, CEO of Procare Health stated, "We are thrilled to start working the collaboration with BioVaxys as it brings a new hope in the field of gynecological cancer.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Medical specialties, Clinical medicine, Papillomavirus, Infectious causes of cancer, Vaccination, Vaccines, Gynaecological cancer, HPV vaccine, Vaccine, Human papillomavirus infection, Cancer vaccine

BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."

Key Points: 
  • BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.Yann Gaslain, CEO of Procare Health stated, "We are thrilled to start working the collaboration with BioVaxys as it brings a new hope in the field of gynecological cancer.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Clinical medicine, Medical specialties, Gynaecological cancer, Vaccines, Cancer vaccines, HPV vaccine, Human papillomavirus infection, Cervical cancer, Vaccine

Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).

Key Points: 
  • Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.

Amid Vaccination Roll Out, Government, Education, and Enterprise Verticals Embrace Everbridge’s Vaccine Distribution Software

Retrieved on: 
Monday, February 8, 2021
Technology, Medical Supplies, Infectious diseases, Security, Software, Biotechnology, Health, Pharmaceutical, Data management, Vaccines, RTT, Medical specialties, Vaccination, Medicine, Biotechnology, Vaccine, Life sciences, HPV vaccine

Utilizing Everbridges vaccine distribution software, more than 190,000 West Virginians have signed up to be vaccinated, with 81% of long-term care facility residents now registered.

Key Points: 
  • Utilizing Everbridges vaccine distribution software, more than 190,000 West Virginians have signed up to be vaccinated, with 81% of long-term care facility residents now registered.
  • View the full release here: https://www.businesswire.com/news/home/20210208005215/en/
    In a conversation with the U.S. Chamber of Commerce Foundation, Governor Justice shared his secrets to vaccination success .
  • Within five days of launch, we have pre-registered more than 100,000 citizens who want to receive the vaccine when doses are made available.
  • The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for residents.

Kroger Announces New Vaccine Payment for All Associates

Retrieved on: 
Friday, February 5, 2021
Medicine, Medical research, Health sciences, Health, Vaccination, Vaccine, Virology, COVID-19 vaccine, Clinical trials, HPV vaccine, Vaccine hesitancy

CINCINNATI, Feb. 5, 2021 /PRNewswire/ -- The Kroger Co. (NYSE: KR) Family of Companies today announced that it will provide a one-time payment of $100 to all associates who receive the fullmanufacturer-recommended doses of the COVID-19 vaccine.

Key Points: 
  • CINCINNATI, Feb. 5, 2021 /PRNewswire/ -- The Kroger Co. (NYSE: KR) Family of Companies today announced that it will provide a one-time payment of $100 to all associates who receive the fullmanufacturer-recommended doses of the COVID-19 vaccine.
  • The one-time $100 vaccine payment will be offered to all associates who receive the fullmanufacturer-recommended doses of the COVID-19 vaccine and present appropriate proof of vaccination to their human resources representative.
  • Associates who cannot receive the vaccine due to medical or religious reasons will have the option of completing an educational health and safety course to receive the payment.
  • We've also welcomed more than 100,000 new associates to The Kroger Family of Companies.

Planned Parenthood of Wisconsin Reminds Women About Importance of Screening During Cervical Cancer Awareness Month and Beyond

Retrieved on: 
Monday, January 25, 2021
Infectious causes of cancer, Gynaecological cancer, Clinical medicine, Papillomavirus, Medicine, Vaccines, Sexually transmitted diseases and infections, Cervical cancer, Human papillomavirus infection, Papilloma, Cancer, HPV vaccine

It is in the spirit of that test that Planned Parenthood of Wisconsin urges women not to put off testing or Human papillomavirus (HPV) vaccinations.

Key Points: 
  • It is in the spirit of that test that Planned Parenthood of Wisconsin urges women not to put off testing or Human papillomavirus (HPV) vaccinations.
  • While January is Cervical Cancer Awareness Month, anytime is a good time to be screened.
  • Hispanic women in Wisconsin are two times more likely than non-Hispanic women to be diagnosed with cervical cancer, and the rate of cervical cancer is 80% higher among Black women than white women.
  • Additionally, Black and Latinx women nationwide are one to two times more likely to die from cervical cancer than white women.